Navigation Links
Trigemina Presents at American Pain Society 32nd Annual Scientific Meeting
Date:5/9/2013

MORAGA, Calif., May 9, 2013 /PRNewswire/ -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, announced that David C. Yeomans , Ph.D., Chief Scientist and Founder, as well as the Director of Pain Research at Stanford University School of Medicine, gave a presentation at the American Pain Society (APS) 32nd Annual Scientific Meeting on May 8th, 2013, in New Orleans, Louisiana.   

Dr. Yeomans was selected by the APS to present data on Trigemina's lead product candidate, TI-001, an intranasal oxytocin pain therapy, during the Clinical and Basic Science Data Blitz event on Wednesday, May 8th, from 6 PM to 8 PM ET.  The blitz was composed of innovative and compelling presentation of new research, with presenters having five minutes to present and an additional five minutes to answer questions from the audience.

"The need to share and discuss new research in pain has become increasingly important, especially when considering the impact that prescription drug abuse has had on our country in recent years," said Dr. Yeomans. "The APS Data Blitz provides researchers and physicians with valuable information on emerging therapies, like TI-001, which may one day provide a safe, non-addictive and effective solution to people suffering from chronic pain."

TI-001 is currently being evaluated in a placebo-controlled, double-blind, randomized-withdrawal and enrollment enriched Phase II clinical study, titled TRIG-05, for efficacy, tolerability and safety in patients with chronic migraine. Promising preclinical and human pilot study results suggests TI-001 could be a safe, non-narcotic form of therapy for the effective relief of chronic migraine, a debilitating condition with few treatment options.  

About Trigemina
Trigemina is focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products. Trigemina's lead product candidate, TI-001, is a patented new application of oxytocin. TI-001 has shown promising results for use as a safe and effective therapy for all forms of chronic and subacute head pain.

For additional information, please visit www.trigemina.com

Contact:

The Ruth Group
Aaron Estrada (media)
aestrada@theruthgroup.com  
(646) 536-7028

Trigemina
Charles Yeomans
cyeomans@trigemina.com
(925) 377-0664


'/>"/>
SOURCE Trigemina, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Trigemina to Present at the 2013 BIO International Convention
2. Trigemina Receives ISP Approval of Clinical Study Protocol for TI-001 Phase 2 Trial
3. Patheon Exhibits and Presents at the 2013 IQPC Global Formulation and Drug Delivery Summit
4. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
5. Assemblyman Levine Presents Resolution Recognizing Rare Disease Day at Capitol
6. Drogueria Americana, a Honduran Affiliate of GeneCell International, Presents to a Panel of More Than 100 Leading Dentist on Dental Pulp Stem Cells
7. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
8. Bluestar Silicones Presents Soft Silicone Advantages At Medical Design And Manufacturing (MD&M) West Show
9. Oracle’s Value Chain Summit San Francisco: Track Sponsor NexInfo presents more industry specific solutions
10. Fertility Associates of Memphis, World-Renowned Expert in Infertility, Presents Findings to European Conference
11. BCA Represents Independent Blood Centers at Phacilitate Cell & Gene Therapy Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... multicenter, prospective clinical study that demonstrates the accuracy of the FebriDx® test, ... clinically significant acute bacterial and viral respiratory tract infections by testing the ...
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
Breaking Biology Technology:
(Date:3/30/2017)... March 30, 2017 The research team of ... three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae ... realm of speed and accuracy for use in identification, crime investigation, ... cost. ... A research ...
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 15.1% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
Breaking Biology News(10 mins):